• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews

Solstice Air banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

About HF0-1234ze(E)

HFO-1234ze(E) FAQs

What is HFO-1234ze(E)’s impact on the environment?

HFO-1234ze(E) has a global warming potential (GWP) close to 1 whereas other propellants have GWPs that range from 138 to 3350 as per the IPCC’s Assessment Report 5. It is estimated that the average inhaler using HFO-1234ze(E) would have carbon emissions of 5-9 g CO2 equivalents per dose, compared to 9 g, 20 g, 263 g, and 697 g CO2 equivalents per dose for DPIs, HFA-152a, HFA-134a, and HFA-227ea inhalers, respectively ­[Jeswani and Azapagic].

What are the details on the flammability? Is it truly non-flammable?

HFO-1234ze(E) is non-flammable at 23°C per ASTM E 681, EC A11, and ISO 10156 testing methods. Under standard conditions of 23°C and 50% relative humidity (RH), HFO-1234ze(E) does not exhibit a flame limit. It is nonflammable per the ASTM D3605 flame projection test, the ignition distance test, and the enclosed space ignition test (closed drum test, GHS Rev. 8). That said, under specific, nonstandard conditions (≥30° C AND ≥50% relative humidity AND a high energy ignition source) HFO-1234ze(E) can exhibit a very narrow flammable range. Typically, in a pharmaceutical manufacturing environment the temperature and humidity are controlled.

What is the compatibility of HFO-1234ze(E) with elastomers?

In a 2011 study, HFO-1234ze(E) was shown to have comparable effects on valve components as the currently used HFA propellants. EPDM, nitrile, chloroprene, butyl, and TPE gaskets were fully immersed in HFO-1234ze(E), HFA-134a, and HFA-227ea for 4 weeks at room temperature and 40°C / 75% RH. The swelling and mechanical resistance were measured for all samples. The swell of elastomers immersed in HFO-1234ze(E), HFA-134a, and HFA-227ea were all acceptable (<5%) and mechanical resistance were all similar.

Is there toxicology information available for HFO-1234ze(E)?

Yes, extensive preclinical toxicological studies have been conducted to characterize the safety of HFO-1234ze(E) in MDI applications. Toxicological data is available upon request. Additionally, safety and tolerability of HFO-1234ze(E) in humans is well established through a phase 1 clinical trial.

Is there a DMF available?

Yes, there is a DMF filed with the US FDA that can be referenced for IND, ANDA, and NDA filings. There are also DMFs filed in Japan and China.

What is the current availability and supply of HFO-1234ze(E), cGMP?

Commercial quantities of HFO-1234ze(E), cGMP, are available from Honeywell's Baton Rouge, LA facility, and sample quantities of cGMP materials, such as 1/2 ton and 50lbs, are available from the Buffalo, NY facility for research and development purposes.

Solstice® Air

Honeywell’s Solstice® Air (HFO-1234ze(E), cGMP) is an alternative medical propellant with a GWP 99.9% lower than propellants currently used in inhaled respiratory medicines. Solstice® Air is the only non-flammable, near-zero GWP propellant available and in clinical development today for pMDIs.      

For references and more information, see:

Solstice Air Overview

Solstice Air Technical Data Sheet


Technical Datasheet

Solstice Air Brochure Cover


Solstice Air Brochure

News

  • UK MHRA approves AstraZeneca’s reformulated Trixeo (Breztri) Aerosphere MDI with HFO-1234ze as the propellant

  • OzUK announces new GLP pilot plant for development of MDIs with LGWP propellants

  • Honeywell announces agreement to supply HFO 1234ze for DevPro albuterol MDI, spin off of the advanced materials business

  • Bespak and H&T Presspart launch new GMP pilot-scale MDI filling line for LGWP propellants

  • AstraZeneca says that it has completed studies to support regulatory submissions for LGWP propellant version of Breztri (Trixeo) Aerosphere MDI

  • Bespak announces that it will soon allocate capacity for new LGWP MDI filling line

  • Bespak and DevPro developing HFO-1234ze albuterol MDI

  • DDL 2023 highlighted novel technologies

  • Oz-UK adds manufacturing line for MDIs with LGWP propellants

  • Recipharm announces appointment of Simon Gardner as Business Development Specialist, partnership with Oz-UK on LGWP MDIs

Contact Us: Click Here

Page sponsored by Honeywell

Primary Sidebar

Sign up for our free weekly newsletter

Secondary Sidebar

Suppliers

Capsules and blisters
Consultants
Contract research
Contract manufacturing
Devices
Education
Excipients
Filling equipment
Instruments
Particle manufacturing
Software and modeling
Solstice Air banner
© 2025 OINDPnews